Background To retrospectively analyze the different fertility-sparing surgery for patients with borderline ovarian tumors, and study their effects on pregnancy outcome and prognosis, to provide guidance and help clinical workers to choose treatment plans. Methods The clinical data of 325 patients with borderline ovarian tumors who underwent fertility-sparing surgery at Shengjing Hospital of China Medical University from 2015 to 2021 were collected. To understand the pregnancy intention and pregnancy outcome of patients through follow-up. The deadline for follow-up was July 2022. After checking and sorting out the data, SPSS25.0 software was used for statistical analysis. Results Among 325 borderline ovarian tumor patients undergoing fertility-sparing surgery, 118 patients had fertility desire. The postoperative pregnancy rate was 57.63% (68/118), and the natural pregnancy rate was 83.82% (57/68). Univariate analysis showed that the selection of surgical methods and routes and CA125 had significant effects on pregnancy outcomes (P < 0.05). The pregnancy rate after cystectomy was 69.57% (32/46), unilateral salpingo-oophorectomy was 70.83% (17/24), unilateral salpingo-oophorectomy + contralateral oophorectomy/cystectomy was 44.00% (11/25), and stage surgery with fertility preservation was 34.78% (8/23). There was a statistical difference between cystectomy and stage operation with fertility preservation (P < 0.0083). The variables P < 0.10 in univariate analysis were included in the logistic regression analysis. The results showed that the surgical method affected the pregnancy outcome, and the difference was statistically significant (P < 0.05). Conclusion Univariate analysis showed that different surgical methods, surgical approaches, and whether CA125 was positive or not affected the postoperative pregnancy rate of borderline ovarian tumors. Multivariate analysis showed that there was a correlation between the operation mode and the pregnancy outcome after the operation. The pregnancy rate after ovarian cystectomy was better than that of stage operation with fertility preservation. The pregnancy rate after laparoscopy was better than that after laparotomy.
Pathological myocardial hypertrophy is a common cardiovascular disease that can progress to heart failure. At present, there is no ideal therapeutic drug in clinical practice. This study aimed to find new therapeutic targets for pathological myocardial hypertrophy. CD9 is a member of the tetraspanin protein family which is widely studied in inflammation and cancer, but has not been studied in pathological cardiac hypertrophy. In this study, we found that the expression of CD9 increased in TAC myocardial tissue. Knockdown of CD9 can alleviate the damage of cardiac function in TAC model, and can reduce heart weight, cardiomyocyte size and degree of fibrosis; overexpression of CD9 can aggravate the damage of cardiac function in TAC model, and can increase cardiac weight, cardiomyocyte size and degree of fibrosis. Mechanistically, Co-IP results showed that CD9 and GP130 can bind to each other in cardiomyocytes, knockdown of CD9 can reduce the protein level of GP130 and phosphorylation of STAT3, and overexpression of CD9 can increase the protein level of GP130 and phosphorylation of STAT3 in vivo and in vitro. Knockdown of GP130 reversed the aggravating effect of CD9 on pathological cardiac hypertrophy. Therefore, we conclude that CD9 exacerbates pathological cardiac hypertrophy through regulating GP130/STAT3 signalling pathway and it may serve as a therapeutic target for pathological cardiac hypertrophy.
ObjectiveThe study retrospectively analyzed the clinical characteristics and prognosis of 17 cases of pregnancy complicated by borderline ovarian tumors to provide help for clinical workers.Materials and MethodsThe clinicopathological data of 17 patients with ovarian borderline tumors during pregnancy at the Shengjing Hospital of China Medical University from January 2015 to June 2021 were collected and analyzed retrospectively. The average age of the patients was 31.82 years (25–45 years), the average number of pregnancies was 2.06 times (1–6 times), and the average number of births was 0.41 times (0–1 time).ResultsAmong the 17 patients, 4 were diagnosed in the first trimester, 2 in the second trimester, and 11 in the third trimester. Most of the first symptoms were cysts, cyst enlargement, or cyst rupture. Among them, 3 cases (1 in the first trimester and 2 in the second trimester) continued pregnancy after a conservative operation, 9 cases underwent cesarean section and a conservative operation simultaneously, and the mother and child had a good outcome. Two cases underwent conservative operations and induced abortion, and 1 case underwent an ectopic pregnancy operation at the same time. The prognosis of the patients was good without recurrence.ConclusionPreoperative diagnosis of borderline ovarian tumors in pregnancy is delayed, and imaging and tumor markers are not specific. The coincidence rate between intraoperative frozen pathology and postoperative paraffin pathology was not high. Borderline tumors are mainly treated by surgery, and the prognosis for mothers and infants is good.
Asymptomatic and perimenopausal women with cervical endometriosis can expect treatment; Patients with milder symptoms are usually managed conservatively with medications, and those with large lesions or significant clinical symptoms require surgery, which is curative in the vast majority of cases postoperatively. Cervical endometriosis is associated with HPV infection and cervical lesions, but further research is still needed to determine their relationship and mechanism.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.